Although FGFR2 mutations are considered rare in ovarian cancer, the Ser252Trp mutation seen in endometrial cancer has also been detected in the ovary cancer 38, suggesting a loss of ligand specificity for FGF signaling in at least some ovarian cancers. This evidence concerns the gene FGFR2 and endometrial cancer.